Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

349 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Comparison of clinical and pathological features of lung lesions of systemic IgG4-related disease and idiopathic multicentric Castleman's disease.
Terasaki Y, Ikushima S, Matsui S, Hebisawa A, Ichimura Y, Izumi S, Ujita M, Arita M, Tomii K, Komase Y, Owan I, Kawamura T, Matsuzawa Y, Murakami M, Ishimoto H, Kimura H, Bando M, Nishimoto N, Kawabata Y, Fukuda Y, Ogura T; Tokyo Diffuse Lung Diseases Study Group. Terasaki Y, et al. Among authors: nishimoto n. Histopathology. 2017 Jun;70(7):1114-1124. doi: 10.1111/his.13186. Epub 2017 Apr 3. Histopathology. 2017. PMID: 28207938
Predictive factors for structural remission using abatacept: Results from the ABROAD study.
Murakami K, Sekiguchi M, Hirata S, Fujii T, Matsui K, Morita S, Ohmura K, Kawahito Y, Nishimoto N, Mimori T, Sano H; ABROAD study investigators. Murakami K, et al. Among authors: nishimoto n. Mod Rheumatol. 2019 May;29(3):406-412. doi: 10.1080/14397595.2018.1482609. Epub 2018 Jun 27. Mod Rheumatol. 2019. PMID: 29807445 Clinical Trial.
Tentative diagnostic criteria and disease severity classification for Castleman disease: A report of the research group on Castleman disease in Japan.
Fujimoto S, Koga T, Kawakami A, Kawabata H, Okamoto S, Mizuki M, Yano S, Ide M, Uno K, Yagi K, Kojima T, Mizutani M, Tokumine Y, Nishimoto N, Fujiwara H, Nakatsuka SI, Shiozawa K, Iwaki N, Masaki Y, Yoshizaki K. Fujimoto S, et al. Among authors: nishimoto n. Mod Rheumatol. 2018 Jan;28(1):161-167. doi: 10.1080/14397595.2017.1366093. Epub 2017 Sep 7. Mod Rheumatol. 2018. PMID: 28880697
Longterm safety and effectiveness of the anti-interleukin 6 receptor monoclonal antibody tocilizumab in patients with systemic juvenile idiopathic arthritis in Japan.
Yokota S, Imagawa T, Mori M, Miyamae T, Takei S, Iwata N, Umebayashi H, Murata T, Miyoshi M, Tomiita M, Nishimoto N, Kishimoto T. Yokota S, et al. Among authors: nishimoto n. J Rheumatol. 2014 Apr;41(4):759-67. doi: 10.3899/jrheum.130690. Epub 2014 Mar 15. J Rheumatol. 2014. PMID: 24634205 Clinical Trial.
Safety and efficacy of tocilizumab, an anti-IL-6-receptor monoclonal antibody, in patients with polyarticular-course juvenile idiopathic arthritis.
Imagawa T, Yokota S, Mori M, Miyamae T, Takei S, Imanaka H, Nerome Y, Iwata N, Murata T, Miyoshi M, Nishimoto N, Kishimoto T. Imagawa T, et al. Among authors: nishimoto n. Mod Rheumatol. 2012 Feb;22(1):109-15. doi: 10.1007/s10165-011-0481-0. Epub 2011 Jun 12. Mod Rheumatol. 2012. PMID: 21667343 Clinical Trial.
Assessment of the validity of the 28-joint disease activity score using erythrocyte sedimentation rate (DAS28-ESR) as a disease activity index of rheumatoid arthritis in the efficacy evaluation of 24-week treatment with tocilizumab: subanalysis of the SATORI study.
Nishimoto N, Takagi N. Nishimoto N, et al. Mod Rheumatol. 2010 Dec;20(6):539-47. doi: 10.1007/s10165-010-0328-0. Epub 2010 Jul 10. Mod Rheumatol. 2010. PMID: 20617358 Free PMC article. Clinical Trial.
349 results